GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Capex-to-Operating-Income

CNTB (Connect Biopharma Holdings) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Connect Biopharma Holdings's Capital Expenditure for the six months ended in Dec. 2024 was $-0.31 Mil. Its Operating Income for the six months ended in Dec. 2024 was $-27.54 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Connect Biopharma Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Connect Biopharma Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Capex-to-Operating-Income Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - 0.09 -

Competitive Comparison of Connect Biopharma Holdings's Capex-to-Operating-Income

For the Biotechnology subindustry, Connect Biopharma Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Connect Biopharma Holdings's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Capex-to-Operating-Income falls into.


;
;

Connect Biopharma Holdings Capex-to-Operating-Income Calculation

Connect Biopharma Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.75) / -22.452
=N/A

Connect Biopharma Holdings's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.314) / -27.54
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Connect Biopharma Holdings  (NAS:CNTB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Connect Biopharma Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings Business Description

Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.